WO2018199530A3 - 대사체 분석을 이용한 베체트병의 진단방법 - Google Patents

대사체 분석을 이용한 베체트병의 진단방법 Download PDF

Info

Publication number
WO2018199530A3
WO2018199530A3 PCT/KR2018/004417 KR2018004417W WO2018199530A3 WO 2018199530 A3 WO2018199530 A3 WO 2018199530A3 KR 2018004417 W KR2018004417 W KR 2018004417W WO 2018199530 A3 WO2018199530 A3 WO 2018199530A3
Authority
WO
WIPO (PCT)
Prior art keywords
behcet
disease
diagnostic method
metabolome analysis
metabolome
Prior art date
Application number
PCT/KR2018/004417
Other languages
English (en)
French (fr)
Other versions
WO2018199530A2 (ko
Inventor
김경헌
차훈석
김정연
안중경
Original Assignee
고려대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려대학교 산학협력단 filed Critical 고려대학교 산학협력단
Priority to JP2019557367A priority Critical patent/JP7179356B2/ja
Priority to CN201880027141.9A priority patent/CN110546505A/zh
Publication of WO2018199530A2 publication Critical patent/WO2018199530A2/ko
Publication of WO2018199530A3 publication Critical patent/WO2018199530A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7206—Mass spectrometers interfaced to gas chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

본 발명은 대사체 분석을 이용한 베체트병 진단방법에 관한 것으로, 대사체학을 이용하여 베체트병을 효과적으로 진단할 수 있는 바이오마커를 제공하며, 이는 베체트병 치료제 개발에도 적용할 수 있다.
PCT/KR2018/004417 2017-04-25 2018-04-17 대사체 분석을 이용한 베체트병의 진단방법 WO2018199530A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019557367A JP7179356B2 (ja) 2017-04-25 2018-04-17 代謝物分析を利用したベーチェット病の診断方法
CN201880027141.9A CN110546505A (zh) 2017-04-25 2018-04-17 利用代谢组分析诊断白塞氏病的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170052665A KR101946884B1 (ko) 2017-04-25 2017-04-25 대사체 분석을 이용한 베체트병의 진단방법
KR10-2017-0052665 2017-04-25

Publications (2)

Publication Number Publication Date
WO2018199530A2 WO2018199530A2 (ko) 2018-11-01
WO2018199530A3 true WO2018199530A3 (ko) 2019-01-10

Family

ID=63920311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/004417 WO2018199530A2 (ko) 2017-04-25 2018-04-17 대사체 분석을 이용한 베체트병의 진단방법

Country Status (4)

Country Link
JP (1) JP7179356B2 (ko)
KR (1) KR101946884B1 (ko)
CN (1) CN110546505A (ko)
WO (1) WO2018199530A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
KR102150837B1 (ko) * 2019-02-22 2020-09-03 고려대학교 산학협력단 소변의 대사체 분석을 위한 소변 샘플 처리 방법
KR102355568B1 (ko) * 2020-07-20 2022-02-07 연세대학교 산학협력단 베체트 장염의 진단용 바이오마커
CN112881668B (zh) * 2021-01-18 2022-04-12 江苏省中医院 两种血清代谢物单独或联合用于制备诊断干燥综合征的试剂盒的用途
CN113539478B (zh) * 2021-06-24 2023-04-07 山西医科大学 基于代谢组学的深静脉血栓形成预测模型的建立方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101516086B1 (ko) * 2013-10-25 2015-05-07 고려대학교 산학협력단 대사체 분석을 이용한 류마티스 관절염 진단방법
KR20150146032A (ko) * 2014-06-20 2015-12-31 고려대학교 산학협력단 혐기성 균의 대사체 분석을 위한 대사체 샘플링 및 처리 방법
KR20160141140A (ko) * 2015-05-28 2016-12-08 고려대학교 산학협력단 대사체 분석을 이용한 베체트병 관절염의 진단방법
KR20160148807A (ko) * 2015-06-16 2016-12-27 연세대학교 산학협력단 장 베체트병 진단용 바이오마커 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100448488B1 (ko) * 2001-09-03 2004-09-13 (주)프로테옴텍 베체트병의 질병 표시인자로서의 아포리포프로테인에이-1을 이용한 진단 시스템
NZ598346A (en) * 2002-07-19 2013-10-25 Abbvie Biotechnology Ltd Treatment of tnf alpha related disorders
JP2006180704A (ja) * 2003-03-05 2006-07-13 Senju Pharmaceut Co Ltd 新規タンパクおよびその用途
AU2008329466B2 (en) * 2007-11-27 2015-04-09 The University Of British Columbia 14-3-3 antagonists for the prevention and treatment of arthritis
JP2016070798A (ja) * 2014-09-30 2016-05-09 学校法人 埼玉医科大学 ベーチェット病の判定を補助する方法、及びベーチェット病の活動性の評価を補助する方法
KR101568632B1 (ko) * 2015-03-02 2015-11-11 연세대학교 산학협력단 Hsc71 단백질에 대한 항체를 포함하는 베체트병 진단 키트
US20180251559A1 (en) * 2015-08-31 2018-09-06 Julie DeMartino Methods for the Modulation of LGALS3BP to Treat Systemic Lupus Erythematosus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101516086B1 (ko) * 2013-10-25 2015-05-07 고려대학교 산학협력단 대사체 분석을 이용한 류마티스 관절염 진단방법
KR20150146032A (ko) * 2014-06-20 2015-12-31 고려대학교 산학협력단 혐기성 균의 대사체 분석을 위한 대사체 샘플링 및 처리 방법
KR20160141140A (ko) * 2015-05-28 2016-12-08 고려대학교 산학협력단 대사체 분석을 이용한 베체트병 관절염의 진단방법
KR20160148807A (ko) * 2015-06-16 2016-12-27 연세대학교 산학협력단 장 베체트병 진단용 바이오마커 및 이의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AHN, JOONG KYONG ET AL.: "A comparative metabolomic evaluation of behcet's d isease with arthritis and seronegative arthritis using synovial fluid", PLOS ONE, 13 January 2015 (2015-01-13), pages e0135856-1 - e0135856-13, XP055679589 *

Also Published As

Publication number Publication date
JP7179356B2 (ja) 2022-11-29
CN110546505A (zh) 2019-12-06
WO2018199530A2 (ko) 2018-11-01
KR101946884B1 (ko) 2019-02-13
KR20180119717A (ko) 2018-11-05
JP2020517935A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
WO2018199530A3 (ko) 대사체 분석을 이용한 베체트병의 진단방법
WO2018209361A3 (en) DIAGNOSIS OF UNIVERSAL PRECISE CANCER
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2018009304A (es) Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.
WO2016184935A3 (en) Method for evaluating manual dexterity
WO2014160441A8 (en) Neuroactive steroids, compositions, and uses thereof
EP3587597A4 (en) METHOD FOR DIAGNOSING PARKINSON'S DISEASE BY BACTERIOLOGICAL METAGENOME ANALYSIS
MY184890A (en) Improved a? protofibril binding antibodies
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
MX2015015907A (es) Metodo no invasivo objetivo para cuantificar el grado de comezon mediante el uso de mediciones psicofisiologicas.
NZ729773A (en) Biomarkers for disease progression in melanoma
WO2015034886A3 (en) Wellness panel for companion animals
EP3571310A4 (en) COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT OF PEROXISOMAL DISEASES
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
WO2014043633A8 (en) Use of e-cadherin and vimentin for selection of treatment responsive patients
EP3656876A4 (en) MIRNA AS A BIOMARKER FOR PARKINSON'S MORBUS AND DIAGNOSTIC KIT WITH IT
MX2020002462A (es) Estratificacion de genotipo en tratamiento y prevencion de diabetes.
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
EP3536805A3 (en) Analytical methods and arrays for use in the same
EP4289970A3 (en) Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis
MX2015017535A (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.
GB2505833A (en) Assessment method

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2019557367

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18792329

Country of ref document: EP

Kind code of ref document: A2